Physician profile
Luxi Chen
NPI 1609455344
$1,196.74
in general payments reported to CMS, 2019-2025
8 companies · $809 in 2025
The $809 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $387 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829 · Education: $193 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.76 |
| Education | $192.98 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $274.99 | 2025 | Ultomiris, Soliris |
| Janssen Biotech, INC. | $264.98 | 2025 | Rybrevant, Carvykti, Darzalex |
| Gilead Sciences, INC. | $168.29 | 2024-2025 | Trodelvy |
| Eisai INC. | $118.84 | 2024 | |
| Amgen INC. | $117.59 | 2024 | Blincyto |
| Astrazeneca Pharmaceuticals LP | $109.72 | 2025 | Datroway |
| Recordati_rare_diseases_inc. | $95.06 | 2025 | Sylvant |
| Pinnacle Biologics, INC | $47.27 | 2024 | Photofrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luxi Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.